Broad phase 11 and pharmacokinetic study of methoxy-morpholino doxorubicin (FCE 23762-MMRDX) in non-small-cell lung cancer, renal cancer and other solid tumour patients
1998

Study of Methoxy-Morpholino Doxorubicin in Cancer Patients

Sample size: 48 publication Evidence: low

Author Information

Author(s): M Bakker, JP Droz, AR Hanauske, J Verweij, AT van Oosterom, HJM Groen, MA Pacciarini, L Domenigoni, F van Weissenbruch, E Pianezzola, EGE de Vries

Primary Institution: University Hospital Groningen, The Netherlands

Hypothesis

The study aims to evaluate the efficacy and pharmacokinetics of methoxymorpholino doxorubicin (MMRDX) in patients with solid tumors resistant to chemotherapy.

Conclusion

MMRDX showed a low response rate in patients with intrinsic chemotherapy resistance, despite its promising pharmacokinetic profile.

Supporting Evidence

  • Patients received a maximum of six cycles of MMRDX.
  • Common side effects included delayed nausea and vomiting, and haematological toxicity.
  • Only one out of 17 evaluable patients with NSCLC had a partial response.

Takeaway

Doctors tested a new cancer drug called MMRDX to see if it could help patients whose tumors didn't respond to other treatments, but it didn't work very well.

Methodology

Patients received MMRDX at 1.5 mg/m² every 4 weeks for up to six cycles, with pharmacokinetic analysis performed on samples collected during the first treatment cycle.

Limitations

The study had a low response rate and included only patients without liver metastases and aged under 65 for pharmacokinetic analysis.

Participant Demographics

Patients included 21 with non-small-cell lung cancer, 19 with renal cancer, and others with various solid tumors, with a median age of 56.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication